Britain and America have secured a important bilateral deal that will guarantee no duties on British pharmaceutical exports being sold in the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This move secures that import taxes on these key products will stay at zero for a period of three years.
This development follows previous statements to dramatically increase duties on patented pharmaceutical products, with increases discussed up to double the cost.
"This agreement with the Britain bolsters the international landscape for cutting-edge drugs and establishes long-overdue balance to American-British medicine commerce," a release said.
Commercial Importance
Medicines constitute one of the Britain's biggest goods shipped to the United States, which is clearly the largest buyer for large UK drugmakers.
Export figures reveal that in the year leading up to September, the UK shipped medicines worth £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that period.
"This guarantee safeguards employment, increases capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The pact involves several key pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be restricted at fifteen percent. Previously, refunds topped twenty percent.
Industry Background
The deal takes place against a long-running dispute between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were heightened by claims that American patients were paying a premium for the identical medicines than people in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or scrapped, while major funding commitments have been pledged toward American operations.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
